Table 1 Demographic and clinical parameters at baseline (V1)

From: NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease

Parameter

Placebo (±sd) n = 10

NR (±sd) n = 10

pa

Sex (female/male)

3/7

2/8

1

Age (years)

65.5 ± 9

61.4 ± 9.28

0.33

Height (cm)

173.9 ± 8.01

177 ± 7.75

0.39

Weight (kg)

81.19 ± 10.90

79.22 ± 11.25

0.69

Time since PD diagnosis (years)

6.9 ± 4.15

5.4 ± 2.91

0.37

BMI (kg/m2)

26.79 ± 2.53

25.24 ± 2.86

0.22

Hoehn & Yahr >2

0

2

0.47

Total MDS-UPDRS

41.8 ± 16.46

51 ± 21.28

0.29

MDS-UPDRS Part I

6.6 ± 3.92

7.8 ± 5.37

0.57

MDS-UPDRS Part II

8.2 ± 2.74

9.4 ± 6.25

0.58

MDS-UPDRS Part III

24.7 ± 11.95

29.7 ± 12.85

0.37

MDS-UPDRS Part IV

2.3 ± 2.94

4.1 ± 4.88

0.33

  1. P-values not corrected for multiple testing. Source data are provided as a Source Data file.
  2. aOne-sided Fisher’s exact test was used for comparing sex ratios and number of participants with Hoehn & Yahr scale score above 2. The remaining parameters were calculated using independent two-tailed t-test for normally distributed data and independent two-tailed Wilcoxon test for non-normally distributed data.
Back to article page